872254-89-2

Basic information

• Product Name: 5-AMINO-3-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)PYRIDINE
• Synonyms: 5-AMINO-3-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)PYRIDINE;5-methyl-6-(4-(trifluoromethyl)phenyl)pyridin-3-amine
• CAS NO: 872254-89-2
• Molecular Formula: C₁₃H₁₁F₃N₂
• Molecular Weight: 252.2350496
• EINECS: -0
• Mol File: 872254-89-2.mol

Chemical Properties

• Boiling Point: 327.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.261±0.06 g/cm3(Predicted)
• PKA: 5.06±0.25(Predicted)
• CAS DataBase Reference: 5-AMINO-3-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-3-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)PYRIDINE(872254-89-2)
• EPA Substance Registry System: 5-AMINO-3-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)PYRIDINE(872254-89-2)

Safety Data

• Hazardous Substances Data: 872254-89-2(Hazardous Substances Data)

Upstream product

• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 23132-21-0 2-bromo-3-methyl-5-nitropyridine 
• 22280-56-4 2-chloro-3-methyl-5-nitropyridine 
• 872254-88-1 3-methyl-5-nitro-2-(4-trifluoromethyl-phenyl)-pyridine 

Downstream Products

• 872254-87-0 5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol 

Relevant articles and documents

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.